lx3

LX-3 is a selective activator of the p38 mitogen-activated protein kinase (MAPK) pathway, which de-represses a subset of endogenous genes repressed by DNA methylation.

BLX3887 is a highly potent and selective inhibitor of 15-lipoxygenase type 1 (15-LO-1), exhibiting an IC50 of 32 nM in cell-free enzyme assays, with marked selectivity over 15-LO-2, which it does not inhibit, as well as over 5-LO (IC50 = 472 nM) and 12-LO (IC50 = 3,310 nM). BLX3887 selectively suppresses 15-LO metabolite production in eosinophils over neutrophils at 10 μM while additionally inhibiting endocytosis and migration of human peripheral blood mononuclear cell–derived dendritic cells in vitro, highlighting its utility in inflammatory and immune cell signaling research.

GLX351322 is NADPH Oxidase 4 Inhibitor with IC50 of 5 μM.

HLX316 (E-688) is an engineered human sialidase fusion protein that targets B7-H3 (CD276). HLX316 removes immunosuppressive sialoglycans from the tumor surface through enzymatic cleavage, thereby neutralizing Siglec-mediated immune evasion. HLX316 also specifically binds to B7-H3 on the surface of tumor cells, enabling precise tumor enrichment. HLX316 is suitable for use in studies of advanced solid tumors.

Pexidartinib (PLX-3397) is a capsule containing a small-molecule receptor tyrosine kinase (RTK) inhibitor targeting KIT, CSF1R, and FLT3, with potential antineoplastic activity.

LX-2931(LX-3305) is a sphingosine-1-phosphate cleavage enzyme (S1P) inhibitor for the treatment of rheumatoid arthritis.

Minzasolmin(DLX-313) is an alpha-synuclein misfolding inhibitor for the study of Parkinson's disease.

Pexidartinib hydrochloride (PLX-3397 HCl) is a selective, orally active, ATP-competitive CSF1R/M-CSFR inhibitor and c-Kit inhibitor with IC50 values of 20 and 10 nM, respectively, capable of inducing cancer cell apoptosis.

RLX-33 is a potent and selective antagonist of relaxin family peptide 3 (RXFP3) that crosses the blood-brain barrier and also blocks relaxin 3-induced ERK1/2 phosphorylation. RLX-33 can block the increase in food intake induced by the RXFP3 selective agonist R3/I5 in rats.RLX-33 can be used to study the metabolic syndrome.

PLX-3618 is an effective BRD4 molecular glue degrader (DC50=12.2 nM) that recruits the E3 ligase substrate receptor DCAF11, promoting BRD4 polyubiquitination and proteasomal degradation to induce apoptosis in AML cells.

BLX-301 is a humanized monoclonal antibody against CD20, exhibiting antitumor activity. It is applicable in studies related to diseases such as non-Hodgkin's lymphoma and rheumatoid arthritis.